| Trial | Sponsor | Phase | Status | Primary completion |
|---|
| VK2735 for Weight Management Phase 3NCT07104500 | VKTX | Phase 3 | Active not recruiting | 2027-07-01Estimated |
| A Study to Assess Anktiva in Patients With Long Covid-19.NCT07108036 | IBRX | Phase 2 | Recruiting | 2026-10Estimated |
| Proof-of-concept Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of SION-719 When Added to TrikaftaNCT07108153 | SION | Phase 2 | Completed | 2026-06-25Actual |
| Assessment of Acute Psychomotor Agitation Measures Associated With Schizophrenia and Bipolar DisorderNCT07116694 | BioXcel Therapeutics Inc | Phase 2 | Completed | 2025-10-07Actual |
| A Study to Examine Anktiva for the Treatment of COVID-19.NCT07123727 | IBRX | Phase 2 | Recruiting | 2027-03Estimated |
| Study of Relapsed/ Refractory B-cell Non- Hodgkin LymphomaNCT07125872 | IBRX | Phase 2 | Recruiting | 2027-05-25Estimated |
| A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With BulevirtideNCT07128550 | VIR | Phase 3 | Active not recruiting | 2026-12Estimated |
| SPN-817 Open-Label Extension Study in Adults With Focal Onset SeizuresNCT07141329 | SUPN | Phase 2 | Enrolling by invitation | 2027-12-31Estimated |
| A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV InfectionNCT07142811 | VIR | Phase 2 | Active not recruiting | 2029-03Estimated |
| Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA)NCT07146022 | MANE | Phase 3 | Active not recruiting | 2027-06Estimated |
| A Study of SPY072 in Rheumatic DiseaseNCT07148414 | SYRE | Phase 2 | Active not recruiting | 2026-10-31Estimated |
| Phase 2b Study of EVO756 in Adults With Atopic DermatitisNCT07150845 | EVMN | Phase 2 | Completed | 2026-07-23Actual |
| Challenge Transfusion of INTERCEPT Pathogen Reduced Red Blood Cells (RBCs) in Subjects With or Without Pre-existing Antibodies to INTERCEPT RBCsNCT07152379 | Cerus Corporation | Phase 2 | Not yet recruiting | 2030-09-30Estimated |
| Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)NCT07154706 | NUVB | Phase 3 | Recruiting | 2030-08-30Estimated |
| A Long-Term Study of Bivamelagon in Participants With Hypothalamic Obesity (HO)NCT07156578 | RYTM | Phase 2 | Enrolling by invitation | 2028-04-15Estimated |
| Early-stage Trial to Determine a Safe and Effective Dose for Ratutrelvir in Patients With Mild to Moderate COVID-19NCT07157007 | TRAW | Phase 2 | Completed | 2026-02-16Actual |
| A Safety and Efficacy Study of GTX-102 in Subjects With Deletion- or Nondeletion-type Angelman Syndrome (AS)NCT07157254 | RARE | Phase 2 | Terminated | 2026-10-30Actual |
| Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AMLNCT07157514 | Actinium Pharmaceuticals | Phase 2, Phase 3 | Not yet recruiting | 2029-02Estimated |
| A Study of SGT-003 Gene Therapy in Ambulant Males With Duchenne Muscular Dystrophy (IMPACT DUCHENNE)NCT07160634 | SLDB | Phase 3 | Recruiting | 2029-01Estimated |
| An Open-Label Extension Study to Evaluate the Safety and Tolerability of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 OLE Study)NCT07161700 | Seaport Therapeutics | Phase 2 | Enrolling by invitation | 2027-05Estimated |
| Study of COYA 302 for the Treatment of ALSNCT07161999 | Coya Therapeutics | Phase 2, Phase 3 | Active not recruiting | 2027-04Estimated |
| A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)NCT07172516 | XENE | Phase 3 | Active not recruiting | 2028-06Estimated |
| An Eight-Week Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry EyeNCT07179055 | Vanda Pharmaceuticals | Phase 2 | Recruiting | 2026-09Estimated |
| Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon MutationsNCT07185997 | AVBP | Phase 3 | Recruiting | 2029-02Estimated |
| SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 DiabetesNCT07187531 | SABS | Phase 2 | Recruiting | 2027-11Estimated |
| A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell TherapyNCT07188558 | LYEL | Phase 3 | Recruiting | 2029-12Estimated |
| 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid TumorsNCT07189871 | RADX | Phase 1, Phase 2 | Recruiting | 2027-12Estimated |
| AURA-IPF: A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of AP02 (Nintedanib Solution) in IPFNCT07194382 | AVLN | Phase 2 | Recruiting | 2026-12Estimated |
| The Hunger Elimination or Reduction Objective (HERO ) Open -Label Extension (OLE) TrialNCT07197034 | AARD | Phase 3 | Terminated | 2026-04-15Actual |
| A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CDI-988 in Healthy Adults After Challenge With Snow Mountain VirusNCT07198139 | COCP | Phase 1, Phase 2 | Completed | 2026-09-14Actual |
Trial details
- Registry ID
- NCT07104500
- Phase
- Phase 3
Trial details
- Registry ID
- NCT07108036
- Phase
- Phase 2
Trial details
- Registry ID
- NCT07108153
- Phase
- Phase 2
Trial details
- Registry ID
- NCT07116694
- Phase
- Phase 2
Trial details
- Registry ID
- NCT07123727
- Phase
- Phase 2
Trial details
- Registry ID
- NCT07125872
- Phase
- Phase 2
Trial details
- Registry ID
- NCT07128550
- Phase
- Phase 3
Trial details
- Registry ID
- NCT07141329
- Phase
- Phase 2
Trial details
- Registry ID
- NCT07142811
- Phase
- Phase 2
Trial details
- Registry ID
- NCT07146022
- Phase
- Phase 3
Trial details
- Registry ID
- NCT07148414
- Phase
- Phase 2
Trial details
- Registry ID
- NCT07150845
- Phase
- Phase 2
Trial details
- Registry ID
- NCT07152379
- Phase
- Phase 2
Trial details
- Registry ID
- NCT07154706
- Phase
- Phase 3
Trial details
- Registry ID
- NCT07156578
- Phase
- Phase 2
Trial details
- Registry ID
- NCT07157007
- Phase
- Phase 2
Trial details
- Registry ID
- NCT07157254
- Phase
- Phase 2
Trial details
- Registry ID
- NCT07157514
- Phase
- Phase 2, Phase 3
Trial details
- Registry ID
- NCT07160634
- Phase
- Phase 3
Trial details
- Registry ID
- NCT07161700
- Phase
- Phase 2
Trial details
- Registry ID
- NCT07161999
- Phase
- Phase 2, Phase 3
Trial details
- Registry ID
- NCT07172516
- Phase
- Phase 3
Trial details
- Registry ID
- NCT07179055
- Phase
- Phase 2
Trial details
- Registry ID
- NCT07185997
- Phase
- Phase 3
Trial details
- Registry ID
- NCT07187531
- Phase
- Phase 2
Trial details
- Registry ID
- NCT07188558
- Phase
- Phase 3
Trial details
- Registry ID
- NCT07189871
- Phase
- Phase 1, Phase 2
Trial details
- Registry ID
- NCT07194382
- Phase
- Phase 2
Trial details
- Registry ID
- NCT07197034
- Phase
- Phase 3
Trial details
- Registry ID
- NCT07198139
- Phase
- Phase 1, Phase 2
Primary completion marks the end of data collection for the main study measures, not a results publication date.